Advancing CAR T cell therapy through the use of multidimensional omics data
Despite the notable success of chimeric antigen receptor (CAR) T cell therapies in the
treatment of certain haematological malignancies, challenges remain in optimizing CAR …
treatment of certain haematological malignancies, challenges remain in optimizing CAR …
[HTML][HTML] Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines …
Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Despite improving outcomes, 40% of patients with newly diagnosed multiple myeloma
treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody …
treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody …
[PDF][PDF] Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy
MH Robinson, NY Villa, DL Jaye… - Journal of Clinical …, 2023 - Am Soc Clin Investig
Entry of antigen-specific T cells into human tumors is critical for immunotherapy, but the
underlying mechanisms are poorly understood. Here, we combined high-dimensional …
underlying mechanisms are poorly understood. Here, we combined high-dimensional …
Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy
AL Garfall, AD Cohen, SP Susanibar-Adaniya… - Blood Cancer …, 2023 - AACR
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-
BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) …
BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) …
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy
Multiple myeloma is characterized by frequent clinical relapses after conventional therapy.
Recently, chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen …
Recently, chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen …
The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception
MV Dhodapkar - American journal of hematology, 2023 - Wiley Online Library
Multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined
significance (MGUS) are distinct disorders that likely originate in the setting of chronic …
significance (MGUS) are distinct disorders that likely originate in the setting of chronic …
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Anti-multiple myeloma B cell maturation antigen (BCMA)-specific chimeric antigen receptor
(CAR) T-cell therapies represent a promising treatment strategy with high response rates in …
(CAR) T-cell therapies represent a promising treatment strategy with high response rates in …
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough …
MI Azeem, AK Nooka, U Shanmugasundaram… - Blood cancer …, 2023 - AACR
Patients with multiple myeloma (MM) mount suboptimal neutralizing antibodies (nAb)
following 2 doses of SARS-CoV-2 mRNA vaccines. Currently, circulating SARS-CoV-2 …
following 2 doses of SARS-CoV-2 mRNA vaccines. Currently, circulating SARS-CoV-2 …
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
A better understanding of the roles of the adaptive and innate immune systems in the
oncogenesis of cancers including multiple myeloma (MM) has led to the development of …
oncogenesis of cancers including multiple myeloma (MM) has led to the development of …